Trades on 1 secondary market

Glyphic Biotechnologies

Glyphic Biotechnologies is a Berkeley, California proteomics company founded in 2021 that is developing ProSE (Protein Sequencing by Expansion) — a de novo, high-throughput, single-molecule protein sequencing technology designed to discriminate all 20 amino acids and their post-translational modific

minimal 14.6 / 100 0 APIs View provider profile →

Company Proteomics Protein Sequencing Biotechnology Life Sciences Single-Molecule Sequencing

Glyphic Biotechnologies is an API provider whose private shares are listed on 1 secondary market: Nasdaq Private Market.

Where It Trades

N Nasdaq Private Market View listing →

Listing data is compiled from the public marketplace pages of Forge Global, Hiive, EquityZen, Nasdaq Private Market, and Augment. A listing indicates that a venue has published a page for this company — it is not an offer, a quote, or investment advice, and APIs.io has no affiliation with any venue.